Status: Recruiting
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve. The sample will be added consecutively and randomized into 2 unblinded groups: the high dosage group will receive a high cabergoline (CAB) dose for a period of \~6 months vs the standard dosage group, which will use the lowest needed dose of CAB to achieve normoprolactinemia for 2 years. The primary outcome will be remission rate.
Participants needed: 70
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of Sao Paulo General HospitalUpdated: Mar 13, 2026Locations: 16
Eligibility criteria
1. Willing and able to provide written informed consent prior to any study-relat... [+13]
1. History of primary hyperparathyroidism [+18]